Daily daraksonrasib pill shrinks and in some patients eliminates pancreatic tumors
Early clinical results show halted tumor growth in nearly all of 61 patients and undetectable tumors in a subset

Researchers announced what they described as the most significant advance in treating pancreatic cancer in decades: a daily oral medicine that appears to shrink—and in some cases eliminate—tumors in patients with one of the deadliest forms of the disease.
Early results show tumor control in a large share of participants
In early clinical testing, scans showed no detectable cancer in one of 12 patients who received daraksonrasib together with chemotherapy. Among a broader group of recently diagnosed patients, investigators report that tumors stopped growing in nearly all of 61 participants with advanced, metastatic pancreatic cancer.
The drug daraksonrasib is already approved in the U.S. and works by blocking and shutting down specific mutations that drive tumor growth in many pancreatic cancers.
Doctors stress caution: it is still unclear how long the therapy can keep the disease at bay and it should not yet be regarded as a cure. The study followed patients for about a year and a half, and for some the cancer did not return during that period.
In the trial’s first phase, tumors stopped increasing in size in 90% of patients; a little more than 60% experienced tumor shrinkage or disappearance; and about 8% became undetectable on scans.
Pancreatic cancer is notoriously difficult to treat and has the lowest survival rate among common cancers. While chemotherapy can produce modest tumor reductions, cancer often returns and most patients with advanced disease survive only months. Symptoms can include jaundice, itchy skin, darker urine, pale stools, unexplained weight loss, fatigue and fever.
Photo: PA)


